查看購物車
  • Simplified Chinese
  • English
2021-2031年亞太地區治療性疫苗市場報告：範圍、細分、動態和競爭分析
市場調查報告書
商品編碼
1871435

2021-2031年亞太地區治療性疫苗市場報告：範圍、細分、動態和競爭分析

Asia Pacific Therapeutic Vaccines Market Report 2021-2031 by Scope, Segmentation, Dynamics, and Competitive Analysis
出版日期: | 出版商: The Insight Partners | 英文 126 Pages | 訂單完成後即時交付

價格

預計亞太地區治療性疫苗市場將顯著成長，到 2031 年將達到約 8,586.288 萬美元，高於 2024 年的 3421.387 萬美元，2024 年至 2031 年的年複合成長率(CAGR) 預計為 14.0%。

執行摘要和市場分析

亞太地區的治療性疫苗市場正經歷強勁成長，主要得益於技術進步和疫苗研發投入的增加。中國和印度是這一成長的主要推動力，兩國人口眾多，免疫接種計劃涵蓋範圍廣，醫療保健支出不斷成長。日本先進的醫療保健體系和高疫苗接種率也顯著促進了市場擴張。此外，澳洲正透過政府的大力支持和提高大眾對疫苗益處的認知，不斷提升其市場佔有率。

儘管市場呈現成長態勢，但仍面臨許多挑戰，例如嚴格的監管架構、高昂的生產和研發成本，以及病患和醫療專業人員認知度有限。應對這些挑戰對於亞太地區治療性疫苗產業的持續發展至關重要。

市場區隔分析

治療性疫苗市場可依產品類型、技術和最終用戶進行細分：

  • 按產品分類：市場分為癌症疫苗、傳染病疫苗和其他疫苗，其中癌症疫苗在 2024 年將佔據最大的市場佔有率。
  • 按技術分類：市場分為同種異體疫苗和自體疫苗，到 2024 年，同種異體疫苗將佔據市場佔有率的領先地位。
  • 按最終用戶分類：最終用戶包括醫院、診所等，其中醫院在 2024 年將佔最大佔有率。

市場展望

對創新治療方案的需求正推動治療性疫苗領域的大量投資和發展。越來越多的候選疫苗正處於不同的研發階段，這就是這一趨勢的體現。生物技術領域的創新研發正在催生針對多種疾病的先進治療性疫苗，包括癌症等慢性疾病和新型感染。例如，Moderna公司的mRNA-4157目前正處於第二期臨床試驗階段，與免疫檢查點抑制劑聯合用於治療黑色素瘤顯示出良好的前景。治療性疫苗研發管線也不斷擴展，以應對自體免疫疾病和傳染病，例如HIV、HPV和HBV。

多家公司正致力於提昇科學技術水平，以研發和推出新型治療性疫苗。針對多種疾病的候選疫苗研發管線不斷擴展，為滿足尚未滿足的醫療需求提供了重要機會。以下是值得關注的治療性疫苗候選產品概要：

  • ADXS11-001：一種處於 I/II 期臨床試驗的子宮頸癌細菌載體疫苗。
  • ISA101：一種用於治療實體瘤的胜肽/蛋白質疫苗，目前處於 II 期臨床試驗階段。
  • NeoVax：一種用於治療腎癌的個人化胜肽疫苗，目前處於 I 期臨床試驗階段。
  • mRNA-4157：一種基於mRNA的新抗原疫苗，目前處於黑色素瘤I/II期臨床試驗階段。
  • VGX-3100：一種用於治療子宮頸癌和頭頸癌的DNA疫苗，目前處於I/II期臨床試驗階段。
  • NASVAC：一種用於治療B型肝炎病毒感染的病毒樣顆粒疫苗，目前處於 III 期臨床試驗階段。
  • iHIVARNA：一種處於 I 期臨床試驗階段的 HIV 感染 mRNA 疫苗。

正在進行的臨床試驗表明，治療性疫苗市場前景光明，新的治療方案不斷湧現，以滿足尚未滿足的醫療需求。

國家概況

亞太地區治療性疫苗市場涵蓋中國、日本、印度、澳洲、韓國等國。預計到2024年，澳洲將保持最大的市場佔有率，這主要得益於其強大的醫療基礎設施和在疫苗研發領域的積極參與。值得注意的是，澳洲研究人員在研發EB病毒（Epstein-Barr virus，EBV）治療性疫苗方面取得了顯著進展，該疫苗有望徹底改變EB病毒相關疾病（包括多發性硬化症和某些癌症）的治療方式。

此外，南澳大利亞州正憑藉其先進的mRNA生產設施BioCina，確立其在mRNA技術領域的領先地位。該設施旨在提高治療藥物和疫苗的產量，並獲得了澳洲政府1000萬美元的資金支持。

公司簡介

治療性疫苗市場的主要參與者包括CureVac SE、THERAVECTYS SA、Transgene SA、INOVIO Pharmaceuticals Inc、ISA Pharmaceuticals BV、Amgen Inc、Merck & Co Inc、印度血清研究所、BioNTech SE和Dendreon。這些公司正採取多種策略，包括擴張、產品創新以及併購，以增強市場佔有率並提供創新產品。

目錄

第1章：引言

第2章：執行概要

  • 關鍵見解

第3章：研究方法

  • 二手研究
  • 初步研究
    • 假設的提出：
    • 宏觀經濟因素分析：
    • 發展基數：
    • 數據三角測量：
    • 國家層面資料：

第4章：亞太地區治療性疫苗市場－主要市場動態

  • 市場促進因素
    • 慢性病盛行率上升
    • 增加疫苗研發的投資與資金投入
  • 市場限制
    • 監管挑戰
  • 市場機遇
    • 拓展產品線
  • 未來趨勢
    • 疫苗技術的進步
  • 駕駛員和安全帶的影響：

第5章：治療性疫苗市場－亞太市場分析

  • 2021-2031年亞太地區治療性疫苗市場收入
  • 亞太地區治療性疫苗市場預測分析

第6章：亞太地區治療性疫苗市場分析－依產品分類

  • 癌症疫苗
  • 傳染病疫苗
  • 其他

第7章：亞太地區治療性疫苗市場分析－依技術分類

  • 同種異體疫苗
  • 自體疫苗

第8章：亞太地區治療性疫苗市場分析－依最終用戶分類

  • 醫院
  • 診所
  • 其他

第9章：亞太地區治療性疫苗市場—國家分析

  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳洲
    • 亞太其他地區

第10章：治療性疫苗市場－產業概況

  • 概述
  • 治療性疫苗市場的成長策略
  • 有機成長策略
    • 概述
  • 無機成長策略
    • 概述

第11章：公司簡介

  • Dendreon
  • BioNTech SE
  • Serum Institute of India Pvt. Ltd
  • Merck & Co Inc
  • Amgen Inc
  • ISA Pharmaceuticals BV
  • INOVIO Pharmaceuticals Inc
  • Transgene SA
  • THERAVECTYS SA
  • CureVac SE

第12章：附錄

Product Code: BMIRE00032092

The Asia Pacific therapeutic vaccines market is projected to grow significantly, reaching approximately US$ 85,862.88 thousand by 2031, up from US$ 34,213.87 thousand in 2024, with an estimated compound annual growth rate (CAGR) of 14.0% from 2024 to 2031.

Executive Summary and Market Analysis

The therapeutic vaccine market in the Asia Pacific region is witnessing robust growth, primarily fueled by advancements in technology and increased funding for vaccine research. Key players in this growth include China and India, which benefit from large populations, extensive immunization programs, and rising healthcare expenditures. Japan's advanced healthcare system and high vaccination rates also contribute significantly to market expansion. Furthermore, Australia is enhancing its market presence through strong government support and heightened public awareness regarding vaccination benefits.

Despite this growth, the market faces challenges such as stringent regulatory frameworks, high production and development costs, and limited awareness among patients and healthcare professionals. Addressing these challenges is crucial for the continued growth of the therapeutic vaccine sector in the Asia Pacific.

Market Segmentation Analysis

The therapeutic vaccines market can be segmented by product type, technology, and end user:

  • By Product: The market is divided into cancer vaccines, infectious disease vaccines, and others, with cancer vaccines holding the largest market share in 2024.
  • By Technology: The market is categorized into allogenic and autologous vaccines, with allogenic vaccines leading in market share in 2024.
  • By End User: The end users include hospitals, clinics, and others, with hospitals accounting for the largest share in 2024.

Market Outlook

The demand for innovative treatment options is driving significant investments and advancements in the therapeutic vaccines sector. The increasing number of clinical candidates progressing through various development stages is indicative of this trend. Innovative research and development in biotechnology are producing advanced therapeutic vaccines targeting a range of diseases, including chronic conditions like cancer and newer infections. For instance, Moderna's mRNA-4157 is currently in phase 2 trials, showing promise in combination with checkpoint inhibitors for melanoma treatment. The therapeutic vaccine pipeline is also expanding to address autoimmune diseases and infectious diseases such as HIV, HPV, and HBV.

Several companies are focusing on scientific and technical excellence to develop and launch new therapeutic vaccines. The expanding pipeline of vaccine candidates targeting diverse diseases presents significant opportunities to meet unmet medical needs. Below is a summary of notable therapeutic vaccine candidates:

  • ADXS11-001: A bacterial vector vaccine in Phase I/II for cervical carcinoma.
  • ISA101: A peptide/protein vaccine in Phase II for solid tumors.
  • NeoVax: A personalized peptide vaccine in Phase I for kidney cancer.
  • mRNA-4157: An mRNA-based neoantigen vaccine in Phase I/II for melanoma.
  • VGX-3100: A DNA vaccine in Phase I/II for cervical and head and neck cancers.
  • NASVAC: A virus-like particle vaccine in Phase III for HBV infection.
  • iHIVARNA: An mRNA vaccine in Phase I for HIV infection.

The ongoing clinical trials indicate a promising future for the therapeutic vaccines market, with new treatment options emerging to address unmet medical needs.

Country Insights

The Asia Pacific therapeutic vaccines market includes countries such as China, Japan, India, Australia, South Korea, and others. Australia is expected to maintain the largest market share in 2024, driven by its strong healthcare infrastructure and active involvement in vaccine development. Notably, Australian researchers have made significant progress in developing a therapeutic vaccine for Epstein-Barr virus (EBV), which could revolutionize treatment for diseases associated with EBV, including multiple sclerosis and certain cancers.

Additionally, South Australia is establishing itself as a leader in mRNA technology with the development of a state-of-the-art mRNA production facility, BioCina. This facility aims to enhance the production of therapeutic drugs and vaccines, supported by US$ 10 million in funding from the Australian government.

Company Profiles

Key players in the therapeutic vaccines market include CureVac SE, THERAVECTYS SA, Transgene SA, INOVIO Pharmaceuticals Inc, ISA Pharmaceuticals BV, Amgen Inc, Merck & Co Inc, Serum Institute of India Pvt. Ltd, BioNTech SE, and Dendreon. These companies are pursuing various strategies, including expansion, product innovation, and mergers and acquisitions, to enhance their market presence and offer innovative products.

Table Of Contents

1. Introduction

  • 1.1 Report Guidance
  • 1.2 Market Segmentation

2. Executive Summary

  • 2.1 Key Insights

3. Research Methodology

  • 3.1 Secondary Research
  • 3.2 Primary Research
    • 3.2.1 Hypothesis formulation:
    • 3.2.2 Macroeconomic factor analysis:
    • 3.2.3 Developing base number:
    • 3.2.4 Data Triangulation:
    • 3.2.5 Country-level data:

4. Asia Pacific Therapeutic Vaccines Market - Key Market Dynamics

  • 4.1 Market Drivers
    • 4.1.1 Rising Prevalence of Chronic Conditions
    • 4.1.2 Increasing Investments and Funding for Vaccine Development
  • 4.2 Market Restraints
    • 4.2.1 Regulatory Challenges
  • 4.3 Market Opportunities
    • 4.3.1 Extending Product Pipeline
  • 4.4 Future Trends
    • 4.4.1 Advancements in Vaccine Technology
  • 4.5 Impact of Drivers and Restraints:

5. Therapeutic Vaccines Market - Asia Pacific Market Analysis

  • 5.1 Asia Pacific Therapeutic Vaccines Market Revenue (US$ Thousand), 2021-2031
  • 5.2 Asia Pacific Therapeutic Vaccines Market Forecast Analysis

6. Asia Pacific Therapeutic Vaccines Market Analysis - by Product

  • 6.1 Cancer Vaccine
    • 6.1.1 Overview
    • 6.1.2 Cancer Vaccine: Asia Pacific Therapeutic Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
  • 6.2 infectious Disease Vaccine
    • 6.2.1 Overview
    • 6.2.2 infectious Disease Vaccine: Asia Pacific Therapeutic Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
  • 6.3 Others
    • 6.3.1 Overview
    • 6.3.2 Others: Asia Pacific Therapeutic Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Thousand)

7. Asia Pacific Therapeutic Vaccines Market Analysis - by Technology

  • 7.1 Allogenic Vaccine
    • 7.1.1 Overview
    • 7.1.2 Allogenic Vaccine: Asia Pacific Therapeutic Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
  • 7.2 Autologous Vaccine
    • 7.2.1 Overview
    • 7.2.2 Autologous Vaccine: Asia Pacific Therapeutic Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Thousand)

8. Asia Pacific Therapeutic Vaccines Market Analysis - by End User

  • 8.1 Hospitals
    • 8.1.1 Overview
    • 8.1.2 Hospitals: Asia Pacific Therapeutic Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
  • 8.2 Clinics
    • 8.2.1 Overview
    • 8.2.2 Clinics: Asia Pacific Therapeutic Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
  • 8.3 Others
    • 8.3.1 Overview
    • 8.3.2 Others: Asia Pacific Therapeutic Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Thousand)

9. Asia Pacific Therapeutic Vaccines Market - Country Analysis

  • 9.1 Asia Pacific
    • 9.1.1 Asia Pacific Therapeutic Vaccines Market - Revenue and Forecast Analysis - by Country
      • 9.1.1.1 Asia Pacific Therapeutic Vaccines Market - Revenue and Forecast Analysis - by Country
      • 9.1.1.2 China: Asia Pacific Therapeutic Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
        • 9.1.1.2.1 China: Asia Pacific Therapeutic Vaccines Market Share - by Product
        • 9.1.1.2.2 China: Asia Pacific Therapeutic Vaccines Market Share - by Technology
        • 9.1.1.2.3 China: Asia Pacific Therapeutic Vaccines Market Share - by End User
      • 9.1.1.3 Japan: Asia Pacific Therapeutic Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
        • 9.1.1.3.1 Japan: Asia Pacific Therapeutic Vaccines Market Share - by Product
        • 9.1.1.3.2 Japan: Asia Pacific Therapeutic Vaccines Market Share - by Technology
        • 9.1.1.3.3 Japan: Asia Pacific Therapeutic Vaccines Market Share - by End User
      • 9.1.1.4 India: Asia Pacific Therapeutic Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
        • 9.1.1.4.1 India: Asia Pacific Therapeutic Vaccines Market Share - by Product
        • 9.1.1.4.2 India: Asia Pacific Therapeutic Vaccines Market Share - by Technology
        • 9.1.1.4.3 India: Asia Pacific Therapeutic Vaccines Market Share - by End User
      • 9.1.1.5 South Korea: Asia Pacific Therapeutic Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
        • 9.1.1.5.1 South Korea: Asia Pacific Therapeutic Vaccines Market Share - by Product
        • 9.1.1.5.2 South Korea: Asia Pacific Therapeutic Vaccines Market Share - by Technology
        • 9.1.1.5.3 South Korea: Asia Pacific Therapeutic Vaccines Market Share - by End User
      • 9.1.1.6 Australia: Asia Pacific Therapeutic Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
        • 9.1.1.6.1 Australia: Asia Pacific Therapeutic Vaccines Market Share - by Product
        • 9.1.1.6.2 Australia: Asia Pacific Therapeutic Vaccines Market Share - by Technology
        • 9.1.1.6.3 Australia: Asia Pacific Therapeutic Vaccines Market Share - by End User
      • 9.1.1.7 Rest of APAC: Asia Pacific Therapeutic Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
        • 9.1.1.7.1 Rest of APAC: Asia Pacific Therapeutic Vaccines Market Share - by Product
        • 9.1.1.7.2 Rest of APAC: Asia Pacific Therapeutic Vaccines Market Share - by Technology
        • 9.1.1.7.3 Rest of APAC: Asia Pacific Therapeutic Vaccines Market Share - by End User

10. Therapeutic Vaccines Market - Industry Landscape

  • 10.1 Overview
  • 10.2 Growth Strategies in the Therapeutic Vaccines Market
  • 10.3 Organic Growth Strategies
    • 10.3.1 Overview
  • 10.4 Inorganic Growth Strategies
    • 10.4.1 Overview

11. Company Profiles

  • 11.1 Dendreon
    • 11.1.1 Key Facts
    • 11.1.2 Business Description
    • 11.1.3 Products and Services
    • 11.1.4 Financial Overview
    • 11.1.5 SWOT Analysis
    • 11.1.6 Key Developments
  • 11.2 BioNTech SE
    • 11.2.1 Key Facts
    • 11.2.2 Business Description
    • 11.2.3 Products and Services
    • 11.2.4 Financial Overview
    • 11.2.5 SWOT Analysis
    • 11.2.6 Key Developments
  • 11.3 Serum Institute of India Pvt. Ltd
    • 11.3.1 Key Facts
    • 11.3.2 Business Description
    • 11.3.3 Products and Services
    • 11.3.4 Financial Overview
    • 11.3.5 SWOT Analysis
    • 11.3.6 Key Developments
  • 11.4 Merck & Co Inc
    • 11.4.1 Key Facts
    • 11.4.2 Business Description
    • 11.4.3 Products and Services
    • 11.4.4 Financial Overview
    • 11.4.5 SWOT Analysis
    • 11.4.6 Key Developments
  • 11.5 Amgen Inc
    • 11.5.1 Key Facts
    • 11.5.2 Business Description
    • 11.5.3 Products and Services
    • 11.5.4 Financial Overview
    • 11.5.5 SWOT Analysis
    • 11.5.6 Key Developments
  • 11.6 ISA Pharmaceuticals BV
    • 11.6.1 Key Facts
    • 11.6.2 Business Description
    • 11.6.3 Products and Services
    • 11.6.4 Financial Overview
    • 11.6.5 SWOT Analysis
    • 11.6.6 Key Developments
  • 11.7 INOVIO Pharmaceuticals Inc
    • 11.7.1 Key Facts
    • 11.7.2 Business Description
    • 11.7.3 Products and Services
    • 11.7.4 Financial Overview
    • 11.7.5 SWOT Analysis
    • 11.7.6 Key Developments
  • 11.8 Transgene SA
    • 11.8.1 Key Facts
    • 11.8.2 Business Description
    • 11.8.3 Products and Services
    • 11.8.4 Financial Overview
    • 11.8.5 SWOT Analysis
    • 11.8.6 Key Developments
  • 11.9 THERAVECTYS SA
    • 11.9.1 Key Facts
    • 11.9.2 Business Description
    • 11.9.3 Products and Services
    • 11.9.4 Financial Overview
    • 11.9.5 SWOT Analysis
    • 11.9.6 Key Developments
  • 11.10 CureVac SE
    • 11.10.1 Key Facts
    • 11.10.2 Business Description
    • 11.10.3 Products and Services
    • 11.10.4 Financial Overview
    • 11.10.5 SWOT Analysis
    • 11.10.6 Key Developments

12. Appendix

  • 12.1 About The Insight Partners
  • 12.2 Glossary of Terms

List Of Tables

  • Table 1. Asia Pacific Therapeutic Vaccines Market Segmentation
  • Table 2. Asia Pacific Therapeutic Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
  • Table 3. Asia Pacific Therapeutic Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Thousand) - by Product
  • Table 4. Asia Pacific Therapeutic Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Thousand) - by Technology
  • Table 5. Asia Pacific Therapeutic Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Thousand) - by End User
  • Table 6. Asia Pacific Therapeutic Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Thousand) - by Country
  • Table 7. China: Asia Pacific Therapeutic Vaccines Market - Revenue and Forecast, 2021 - 2031 (US$ Thousand) - by Product
  • Table 8. China: Asia Pacific Therapeutic Vaccines Market - Revenue and Forecast, 2021 - 2031 (US$ Thousand) - by Technology
  • Table 9. China: Asia Pacific Therapeutic Vaccines Market - Revenue and Forecast, 2021 - 2031 (US$ Thousand) - by End User
  • Table 10. Japan: Asia Pacific Therapeutic Vaccines Market - Revenue and Forecast, 2021 - 2031 (US$ Thousand) - by Product
  • Table 11. Japan: Asia Pacific Therapeutic Vaccines Market - Revenue and Forecast, 2021 - 2031 (US$ Thousand) - by Technology
  • Table 12. Japan: Asia Pacific Therapeutic Vaccines Market - Revenue and Forecast, 2021 - 2031 (US$ Thousand) - by End User
  • Table 13. India: Asia Pacific Therapeutic Vaccines Market - Revenue and Forecast, 2021 - 2031 (US$ Thousand) - by Product
  • Table 14. India: Asia Pacific Therapeutic Vaccines Market - Revenue and Forecast, 2021 - 2031 (US$ Thousand) - by Technology
  • Table 15. India: Asia Pacific Therapeutic Vaccines Market - Revenue and Forecast, 2021 - 2031 (US$ Thousand) - by End User
  • Table 16. South Korea: Asia Pacific Therapeutic Vaccines Market - Revenue and Forecast, 2021 - 2031 (US$ Thousand) - by Product
  • Table 17. South Korea: Asia Pacific Therapeutic Vaccines Market - Revenue and Forecast, 2021 - 2031 (US$ Thousand) - by Technology
  • Table 18. South Korea: Asia Pacific Therapeutic Vaccines Market - Revenue and Forecast, 2021 - 2031 (US$ Thousand) - by End User
  • Table 19. Australia: Asia Pacific Therapeutic Vaccines Market - Revenue and Forecast, 2021 - 2031 (US$ Thousand) - by Product
  • Table 20. Australia: Asia Pacific Therapeutic Vaccines Market - Revenue and Forecast, 2021 - 2031 (US$ Thousand) - by Technology
  • Table 21. Australia: Asia Pacific Therapeutic Vaccines Market - Revenue and Forecast, 2021 - 2031 (US$ Thousand) - by End User
  • Table 22. Rest of APAC: Asia Pacific Therapeutic Vaccines Market - Revenue and Forecast, 2021 - 2031 (US$ Thousand) - by Product
  • Table 23. Rest of APAC: Asia Pacific Therapeutic Vaccines Market - Revenue and Forecast, 2021 - 2031 (US$ Thousand) - by Technology
  • Table 24. Rest of APAC: Asia Pacific Therapeutic Vaccines Market - Revenue and Forecast, 2021 - 2031 (US$ Thousand) - by End User
  • Table 25. Recent Organic Growth Strategies in the Therapeutic Vaccines Market
  • Table 26. Recent Inorganic Growth Strategies in the Therapeutic Vaccines Market
  • Table 27. Glossary of Terms, Therapeutic Vaccines Market

List Of Figures

  • Figure 1. Asia Pacific Therapeutic Vaccines Market Segmentation - Country
  • Figure 2. Asia Pacific Therapeutic Vaccines Market - Key Market Dynamics
  • Figure 3. Impact Analysis of Drivers and Restraints
  • Figure 4. Asia Pacific Therapeutic Vaccines Market Revenue (US$ Thousand), 2021-2031
  • Figure 5. Asia Pacific Therapeutic Vaccines Market Share (%) - by Product (2024 and 2031)
  • Figure 6. Cancer Vaccine: Asia Pacific Therapeutic Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
  • Figure 7. infectious Disease Vaccine: Asia Pacific Therapeutic Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
  • Figure 8. Others: Asia Pacific Therapeutic Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
  • Figure 9. Asia Pacific Therapeutic Vaccines Market Share (%) - by Technology (2024 and 2031)
  • Figure 10. Allogenic Vaccine: Asia Pacific Therapeutic Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
  • Figure 11. Autologous Vaccine: Asia Pacific Therapeutic Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
  • Figure 12. Asia Pacific Therapeutic Vaccines Market Share (%) - by End User (2024 and 2031)
  • Figure 13. Hospitals: Asia Pacific Therapeutic Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
  • Figure 14. Clinics: Asia Pacific Therapeutic Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
  • Figure 15. Others: Asia Pacific Therapeutic Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
  • Figure 16. Asia Pacific Therapeutic Vaccines Market Breakdown, by Key Countries, 2024 and 2031 (%)
  • Figure 17. China: Asia Pacific Therapeutic Vaccines Market - Revenue and Forecast, 2021- 2031 (US$ Thousand)
  • Figure 18. Japan: Asia Pacific Therapeutic Vaccines Market - Revenue and Forecast, 2021- 2031 (US$ Thousand)
  • Figure 19. India: Asia Pacific Therapeutic Vaccines Market - Revenue and Forecast, 2021- 2031 (US$ Thousand)
  • Figure 20. South Korea: Asia Pacific Therapeutic Vaccines Market - Revenue and Forecast, 2021- 2031 (US$ Thousand)
  • Figure 21. Australia: Asia Pacific Therapeutic Vaccines Market - Revenue and Forecast, 2021- 2031 (US$ Thousand)
  • Figure 22. Rest of APAC: Asia Pacific Therapeutic Vaccines Market - Revenue and Forecast, 2021- 2031 (US$ Thousand)
  • Figure 23. Growth Strategies in the Therapeutic Vaccines Market